These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

167 related items for PubMed ID: 8375734

  • 21. Intraperitoneal high-dose cisplatin and etoposide with systemic thiosulfate protection in second-line treatment of advanced ovarian cancer.
    Malmström H, Rasmussen S, Simonsen E.
    Gynecol Oncol; 1993 May; 49(2):166-71. PubMed ID: 8504983
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
    Abali H, Urün Y, Oksüzoğlu B, Budakoğlu B, Yildirim N, Güler T, Ozet G, Zengin N.
    Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Intraperitoneal carboplatin and etoposide for persistent epithelial ovarian cancer: analysis of results by prior sensitivity to platinum-based regimens.
    Muggia FM, Groshen S, Russell C, Jeffers S, Chen SC, Schlaerth J, Curtin J, Morrow CP.
    Gynecol Oncol; 1993 Aug; 50(2):232-8. PubMed ID: 8375739
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A phase I-II study with intraperitoneal cisplatin plus systemic etoposide in patients with minimal residual ovarian cancer.
    Willemse PH, Sleijfer DT, de Vries EG, Boonstra H, Bouma J, Mulder NH.
    Eur J Cancer; 1992 Aug; 28(2-3):479-81. PubMed ID: 1591067
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 35. Treatment for recurrent ovarian cancer. A report of 2 cases.
    Maxwell AM, Jordaan JP.
    S Afr Med J; 1987 Feb 07; 71(3):180. PubMed ID: 3810370
    [Abstract] [Full Text] [Related]

  • 36. A phase II trial of intraperitoneal cisplatin and etoposide as salvage treatment for minimal residual ovarian carcinoma.
    Kirmani S, Lucas WE, Kim S, Goel R, McVey L, Morris J, Howell SB.
    J Clin Oncol; 1991 Apr 07; 9(4):649-57. PubMed ID: 2066761
    [Abstract] [Full Text] [Related]

  • 37. Impact on survival of surgically defined favorable responses to salvage intraperitoneal chemotherapy in small-volume residual ovarian cancer.
    Markman M, Reichman B, Hakes T, Lewis JL, Jones W, Rubin S, Barakat R, Curtin J, Almadrones L, Hoskins W.
    J Clin Oncol; 1992 Sep 07; 10(9):1479-84. PubMed ID: 1517791
    [Abstract] [Full Text] [Related]

  • 38. [Carboplatin and etoposide combination for the treatment of recurrent epithelial ovarian cancer].
    Chauvergne J, Chinet-Charrot P, Stöckle E, Thomas L, Toulouse C.
    Bull Cancer; 1996 Apr 07; 83(4):315-23. PubMed ID: 8680083
    [Abstract] [Full Text] [Related]

  • 39. A phase II trial of intraperitoneal cisplatin and etoposide for primary treatment of ovarian epithelial cancer.
    Howell SB, Kirmani S, Lucas WE, Zimm S, Goel R, Kim S, Horton MC, McVey L, Morris J, Weiss RJ.
    J Clin Oncol; 1990 Jan 07; 8(1):137-45. PubMed ID: 2295904
    [Abstract] [Full Text] [Related]

  • 40. The current therapeutic approaches to advanced ovarian cancer.
    Nishimura H, Hamaguchi K, Miyahara K, Tazaki T, Tateno N, Yakushiji M.
    Nihon Sanka Fujinka Gakkai Zasshi; 1990 Dec 07; 42(12):1691-6. PubMed ID: 2277209
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 9.